I remember from the time when Simcere first came in the picture we asked the same question about royalties.
The answer those days was that we would receive 7 % royalties on all sales from China.
So that is very much the same with the only difference that those days nothing happened with the partnership.
Now it seems we will some REAL production and SALES coming from China.
Lucky the Chinese know how to get on with things, especially if there is money to be made, so its up to GSK to do their part.
It basically will mean more royalties flowing to Biota and that is a good thing.
Even with Lani coming on the market I can see a cheaper version Relenza as now soon to be produced in China, becoming a healthy earner for the next 5 years or so.
jojo
BTA Price at posting:
$2.04 Sentiment: LT Buy Disclosure: Held
